Novo Nordisk stock just had its worst day since Black Monday, after the maker of Ozempic and Wegovy slashed its 2025 outlook.

La farmacéutica danesa espera un crecimiento menor, lo que supone su segundo recorte de estimaciones en lo que va de año

The Danish weight loss drug-maker claims "knock-off" treatments are hitting growth.